Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed, et al.
The Lancet (2018) Vol. 392, Iss. 10157, pp. 1519-1529
Open Access | Times Cited: 1481

Showing 1-25 of 1481 citing articles:

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Juhani Knuuti, William Wijns, Antti Saraste, et al.
European Heart Journal (2019) Vol. 41, Iss. 3, pp. 407-477
Open Access | Times Cited: 6028
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Frank L.J. Visseren, François Mach, Yvo M. Smulders, et al.
European Heart Journal (2021) Vol. 42, Iss. 34, pp. 3227-3337
Open Access | Times Cited: 4328
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Jean‐Philippe Collet, Hölger Thiele, Emanuele Barbato, et al.
European Heart Journal (2020) Vol. 42, Iss. 14, pp. 1289-1367
Open Access | Times Cited: 4214
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Donna K. Arnett, Roger S. Blumenthal, Michelle A. Albert, et al.
Circulation (2019) Vol. 140, Iss. 11
Open Access | Times Cited: 4192
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino, Peter J Grant, Victor Aboyans, et al.
European Heart Journal (2019) Vol. 41, Iss. 2, pp. 255-323
Open Access | Times Cited: 4130
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Donna K. Arnett, Roger S. Blumenthal, Michelle A. Albert, et al.
Circulation (2019) Vol. 140, Iss. 11
Open Access | Times Cited: 3531
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, et al.
The Lancet (2019) Vol. 394, Iss. 10193, pp. 121-130
Closed Access | Times Cited: 2256
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
Dawn Kleindorfer, Amytis Towfighi, Seemant Chaturvedi, et al.
Stroke (2021) Vol. 52, Iss. 7
Open Access | Times Cited: 2028
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Donna K. Arnett, Roger S. Blumenthal, Michelle A. Albert, et al.
Journal of the American College of Cardiology (2019) Vol. 74, Iss. 10, pp. e177-e232
Open Access | Times Cited: 1490
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, et al.
New England Journal of Medicine (2019) Vol. 381, Iss. 9, pp. 841-851
Open Access | Times Cited: 1441
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Søren Lund Kristensen, Rasmus Rørth, Pardeep S. Jhund, et al.
The Lancet Diabetes & Endocrinology (2019) Vol. 7, Iss. 10, pp. 776-785
Open Access | Times Cited: 1291
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
Donna K. Arnett, Roger S. Blumenthal, Michelle A. Albert, et al.
Journal of the American College of Cardiology (2019) Vol. 74, Iss. 10, pp. 1376-1414
Open Access | Times Cited: 1006
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Molecular Metabolism (2020) Vol. 46, pp. 101102-101102
Open Access | Times Cited: 992
KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Ian H. de Boer, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2020) Vol. 98, Iss. 4, pp. S1-S115
Open Access | Times Cited: 962
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar, Matthew M.Y. Lee, Søren Lund Kristensen, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 10, pp. 653-662
Open Access | Times Cited: 947
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Peter Rossing, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2022) Vol. 102, Iss. 5, pp. S1-S127
Open Access | Times Cited: 714
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
Nikolaus Marx, Massimo Federici, Katharina Schütt, et al.
European Heart Journal (2023) Vol. 44, Iss. 39, pp. 4043-4140
Open Access | Times Cited: 698
Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies
Suowen Xu, Iqra Ilyas, Peter J. Little, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 3, pp. 924-967
Open Access | Times Cited: 697
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus
Thomas A. Zelniker, Stephen D. Wiviott, Itamar Raz, et al.
Circulation (2019) Vol. 139, Iss. 17, pp. 2022-2031
Closed Access | Times Cited: 672
The Discovery and Development of Liraglutide and Semaglutide
Lotte Bjerre Knudsen, Jesper Lau
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 634
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Circulation (2023) Vol. 148, Iss. 9
Open Access | Times Cited: 587
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary
Alan J. Garber, Yehuda Handelsman, George Grunberger, et al.
Endocrine Practice (2020) Vol. 26, Iss. 1, pp. 107-139
Open Access | Times Cited: 548
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, et al.
The Lancet (2019) Vol. 394, Iss. 10193, pp. 131-138
Closed Access | Times Cited: 527
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
Suetonia C. Palmer, Britta Tendal, Reem A. Mustafa, et al.
BMJ (2021), pp. m4573-m4573
Open Access | Times Cited: 485
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Stefano Del Prato, Steven E. Kahn, Imre Pávó, et al.
The Lancet (2021) Vol. 398, Iss. 10313, pp. 1811-1824
Closed Access | Times Cited: 434
Page 1 - Next Page

Scroll to top